Development
GSK plc
GSK
$42.44
$0.821.97%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 6.13B | 7.45B | 18.34B | 17.36B | 17.97B |
| Total Depreciation and Amortization | 2.85B | 1.91B | 2.30B | 2.89B | 2.67B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 494.55M | 1.85B | -10.35B | -10.33B | -9.75B |
| Change in Net Operating Assets | -1.00B | -4.47B | -4.79B | -4.00B | -1.63B |
| Cash from Operations | 8.47B | 6.74B | 5.49B | 5.91B | 9.26B |
| Capital Expenditure | -1.64B | -1.55B | -1.49B | -1.42B | -1.40B |
| Sale of Property, Plant, and Equipment | 34.88M | 182.39M | 176.71M | 172.95M | 172.50M |
| Cash Acquisitions | -1.84B | -1.93B | -5.42B | -3.73B | -3.76B |
| Divestitures | 61.60M | 42.10M | 36.40M | -60.05M | -51.42M |
| Other Investing Activities | 1.39B | 297.35M | -454.49M | -1.60B | -5.93B |
| Cash from Investing | -1.99B | -2.96B | -7.16B | -6.63B | -10.96B |
| Total Debt Issued | 223.00M | 2.87B | 4.29B | 2.60B | 2.05B |
| Total Debt Repaid | -2.79B | -3.07B | -4.60B | -6.76B | -6.87B |
| Issuance of Common Stock | 12.00M | 11.00M | 19.00M | 23.00M | 32.00M |
| Repurchase of Common Stock | -2.00M | -2.00M | -2.00M | -2.00M | -7.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.79B | -2.86B | -2.97B | -3.72B | -4.33B |
| Other Financing Activities | -837.00M | -856.00M | -187.00M | -256.00M | 9.09B |
| Cash from Financing | -7.04B | -4.15B | -3.48B | -9.16B | 1.93B |
| Foreign Exchange rate Adjustments | -122.10M | -25.84M | -27.89M | 132.68M | 186.43M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -682.07M | -395.10M | -5.17B | -9.75B | 413.80M |